Investor Relations

For press releases prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Theravance, Inc. Investor Relations Press Releases.


Press Releases
Date Title and Summary View
Mar 12, 2015 GEORGE TOWN, GRAND CAYMAN -- (Marketwired) -- 03/12/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced the initiation of a Phase 2b study of velusetrag (TD-5108), an investigational drug for the treatment of patients with gastroparesis and other gastrointestinal motility disorders. ...
Mar 10, 2015 GEORGE TOWN, GRAND CAYMAN -- (Marketwired) -- 03/10/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today reported financial results for the fourth quarter and year ending December 31, 2014. Revenue for the fourth quarter of 2014 was $1.4 million. Net loss for the fourth quarter of 2014 was $64.3 milli...
Mar 4, 2015 GEORGE TOWN, CAYMAN ISLANDS -- (Marketwired) -- 03/04/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (the "Company") announced today that stock options to purchase an aggregate of 10,500 of the Company's ordinary shares were granted to three new non-executive officer employees on March 2, 2015. The options were granted in accordance with NASD...
Mar 3, 2015 GEORGE TOWN, GRAND CAYMAN -- (Marketwired) -- 03/03/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended December 31, 2014 after market close on Tuesday, March 10, 2015. An accompanying conference call will be held at 5:...
Feb 24, 2015 GEORGE TOWN, GRAND CAYMAN -- (Marketwired) -- 02/24/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced enrollment of the first patient in the Company's Phase 3 registrational study of telavancin in patients with Staphylococcus aureus bacteremia. The trial is designed to support a regulator...
Feb 10, 2015 GEORGE TOWN, GRAND CAYMAN -- (Marketwired) -- 02/10/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced enrollment of the first patient in the Company's Telavancin Observational Use Registry (TOUR). The study is designed to assess how VIBATIV® (telavancin), the Company's proprietary FD...
Feb 4, 2015 GEORGE TOWN, CAYMAN ISLANDS -- (Marketwired) -- 02/04/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that Renee Gala, Chief Financial Officer, Brett Haumann, Senior Vice President, Clinical Development and Operations, and Frank Pasqualone, Senior Vice President, Operations will participate in a fireside chat at the 2015 Leerin...
Feb 3, 2015 GEORGE TOWN, CAYMAN ISLANDS -- (Marketwired) -- 02/03/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (the "Company") announced today that stock options to purchase an aggregate of 34,375 of the Company's ordinary shares were granted to 14 new non-executive officer employees on February 2, 2015. The options were granted in accordance with NASD...
Feb 2, 2015 GEORGE TOWN, CAYMAN ISLANDS and PITTSBURGH, PA -- (Marketwired) -- 02/02/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) and Mylan Inc. (NASDAQ: MYL) today announced that the two companies will partner on the development and, subject to FDA approval, commercialization of TD-4208, a novel investigational once-daily nebulized long-acting muscari...
Jan 5, 2015 SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 01/05/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today, through its U.S. operating subsidiary, Theravance Biopharma US, Inc., that stock options to purchase an aggregate of 114,500 of the Company's ordinary shares were granted to seven new non-...
1
NextLast
Add to Briefcase = add release to Briefcase
By clicking on the link below, you will leave www.theravance.com.
CancelContinue
Form content here please :)